1. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Issue 1 (30th December 2016) Authors: Taniguchi, Hirokazu; Takeuchi, Shinji; Fukuda, Koji; Nakagawa, Takayuki; Arai, Sachiko; Nanjo, Shigeki; Yamada, Tadaaki; Yamaguchi, Hiroyuki; Mukae, Hiroshi; Yano, Seiji Journal: Cancer science Issue: Volume 108:Issue 1(2017) Page Start: 53 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study). Issue 4 (24th May 2021) Authors: Izumi, Kouji; Iwamoto, Hiroaki; Yaegashi, Hiroshi; Nohara, Takahiro; Shigehara, Kazuyoshi; Kadono, Yoshifumi; Nanjo, Shigeki; Yamada, Tadaaki; Ohtsubo, Koshiro; Yano, Seiji; Mizokami, Atsushi Journal: Journal of cachexia, sarcopenia and muscle Issue: Volume 12:Issue 4(2021) Page Start: 831 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4‐ALK lung cancer cell line. Issue 3 (17th February 2015) Authors: Nanjo, Shigeki; Nakagawa, Takayuki; Takeuchi, Shinji; Kita, Kenji; Fukuda, Koji; Nakada, Mitsutoshi; Uehara, Hisanori; Nishihara, Hiroshi; Hara, Eiji; Uramoto, Hidetaka; Tanaka, Fumihiro; Yano, Seiji Journal: Cancer science Issue: Volume 106:Issue 3(2015:Mar.) Page Start: 244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Organ‐specific efficacy of HSP90 inhibitor in multiple‐organ metastasis model of chemorefractory small cell lung cancer. Issue 5 (13th October 2015) Authors: Takeuchi, Shinji; Fukuda, Koji; Arai, Sachiko; Nanjo, Shigeki; Kita, Kenji; Yamada, Tadaaki; Hara, Eiji; Nishihara, Hiroshi; Uehara, Hisanori; Yano, Seiji Journal: International journal of cancer Issue: Volume 138:Issue 5(2016:Mar. 01) Page Start: 1281 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer. (September 2017) Authors: Hata, Akito; Katakami, Nobuyuki; Nanjo, Shigeki; Okuda, Chiyuki; Kaji, Reiko; Masago, Katsuhiro; Fujita, Shiro; Yoshida, Hiroshi; Zama, Kota; Imai, Yukihiro; Hirata, Yukio Journal: Lung cancer Issue: Volume 111(2017) Page Start: 182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor. Issue 24 (16th September 2013) Authors: Hata, Akito; Katakami, Nobuyuki; Yoshioka, Hiroshige; Takeshita, Jumpei; Tanaka, Kosuke; Nanjo, Shigeki; Fujita, Shiro; Kaji, Reiko; Imai, Yukihiro; Monden, Kazuya; Matsumoto, Takeshi; Nagata, Kazuma; Otsuka, Kyoko; Tachikawa, Ryo; Tomii, Keisuke; Kunimasa, Kei; Iwasaku, Masahiro; Nishiyama, Akih... Journal: Cancer Issue: Volume 119:Issue 24(2013) Page Start: 4325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor: Comparison between T790M mutation‐positive and mutation‐negative populations. Issue 24 (16th September 2013) Authors: Hata, Akito; Katakami, Nobuyuki; Yoshioka, Hiroshige; Takeshita, Jumpei; Tanaka, Kosuke; Nanjo, Shigeki; Fujita, Shiro; Kaji, Reiko; Imai, Yukihiro; Monden, Kazuya; Matsumoto, Takeshi; Nagata, Kazuma; Otsuka, Kyoko; Tachikawa, Ryo; Tomii, Keisuke; Kunimasa, Kei; Iwasaku, Masahiro; Nishiyama, Akih... Journal: Cancer Issue: Volume 119:Issue 24(2013) Page Start: 4325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The novel phosphoinositide 3‐kinase–mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Issue 2 (12th February 2013) Authors: Sano, Takako; Takeuchi, Shinji; Nakagawa, Takayuki; Ishikawa, Daisuke; Nanjo, Shigeki; Yamada, Tadaaki; Nakamura, Takahiro; Matsumoto, Kunio; Yano, Seiji Journal: International journal of cancer Issue: Volume 133:Issue 2(2013:Jul. 15) Page Start: 505 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Trametinib overcomes KRAS‐G12V–induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR‐mutant lung cancer. Issue 9 (22nd July 2021) Authors: Fukuda, Koji; Otani, Sakiko; Takeuchi, Shinji; Arai, Sachiko; Nanjo, Shigeki; Tanimoto, Azusa; Nishiyama, Akihiro; Naoki, Katsuhiko; Yano, Seiji Journal: Cancer science Issue: Volume 112:Issue 9(2021) Page Start: 3784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗